Record Year for Alzheimer’s Research UK as Income Reaches £42.2m

Alzheimer’s Research UK is celebrating a year that has seen it bounce back from one of the most challenging periods to date to invest more in research than ever before.

Overall, the UK’s leading dementia research charity reached an income for 2021/22 of £42.2m, with an incredible £39.2m of that coming from donations. As a result, the Cambridgeshire-based charity was able to invest £28.6m in its charitable activities including £23.6m in pioneering dementia research.

This record financial performance follows a challenging year for the charity due to COVID-19. During the pandemic, Alzheimer’s Research UK was forced to put much of its usual activity on hold, labs were hit by closures and restrictions, and fundraising activities were cancelled or curtailed. But 2021/22 saw the charity emerge stronger and more determined to help bring about life-changing treatments for people affected by dementia.

Shirley Cramer, Interim Chief Executive of Alzheimer’s Research UK, said:
“We were always open and vocal about the challenges we faced due to the pandemic, and we are humbled that our supporters rallied around us and have continued to as personal finances become more squeezed than ever. We had always pledged to redouble our efforts as soon as we were able to, and thanks to all those who continued to donate, fundraise and volunteer their time, we’ve been able to do just that. We’re privileged to have such an amazing community of people standing with us in our mission to bring about life-changing treatments for dementia, the need has never been greater.

“We’re proud to have been able to continue our work to support early career researchers, launching new long-term initiatives to keep these scientists working on dementia and supporting them to become future leaders. These last two years have been particularly hard for all those affected by dementia – a condition that remains one of our leading causes of death and still has no treatments available in the UK that can stop or slow the underlying disease. We’re making incredible progress and we are hugely grateful to all those who have made this progress possible – we’ll keep working to transform the lives of everyone affected by dementia.”